Tran, Ben
11 papers on CoChatORCID 0000-0001-9124-354X
Most cited papers
- Verified
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
Buteau, J. P., Martin, A. J., Emmett, L., Iravani, A., Sandhu, S., Joshua, A. M., Francis, R. J., Zhang, A. Y., Scott, A. M., Lee, S.-T., et al. (2022) · The Lancet Oncology
Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research
Cited by 296
- Verified
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177 Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
Violet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., et al. (2020) · Journal of Nuclear Medicine
Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research
Cited by 292
- Verified
Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)
Goldstein, J., Tran, B., Ensor, J., Gibbs, P., Wong, H. L., Wong, S. F., Vilar, E., Tie, J., Broaddus, R., Kopetz, S., et al. (2014) · Annals of Oncology
Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer
Cited by 288
- Verified
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Buteau, J. P., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., et al. (2024) · The Lancet Oncology
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 230
- Verified
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
Dovedi, S. J., Elder, M. J., Yang, C., Sitnikova, S. I., Irving, L., Hansen, A., Hair, J., Jones, D. C., Hasani, S., Wang, B., et al. (2021) · Cancer Discovery
Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research
Cited by 186
- Verified
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Dorff, T., Horvath, L. G., Autio, K., Bernard-Tessier, A., Rettig, M. B., Machiels, J.-P., Bilen, M. A., Lolkema, M. P., Adra, N., Rottey, S., et al. (2024) · Clinical Cancer Research
Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors
Cited by 76
- Verified
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
Annala, M., Fu, S., Bacon, J. V. W., Sipola, J., Iqbal, N., Ferrario, C., Ong, M., Wadhwa, D., Hotte, S. J., Lo, G., et al. (2021) · Annals of Oncology
Prostate Cancer Treatment and ResearchBone health and treatments
Cited by 73
- Verified
e-TC: Development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer
Heiniger, L. E., Smith, A. B., Olver, I., Grimison, P., Klein, B., Wootten, A., Abbott, J.-A. M., Price, M. A., McJannett, M., Tran, B., et al. (2017) · European Journal of Cancer Care
Cancer survivorship and careDigital Mental Health Interventions
Cited by 32
- Verified
TAS‐102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial
Mayer, R. J., Ohtsu, A., Yoshino, T., Falcone, A., Garcia-Carbonero, R., Tabernero, J., Sobrero, A. F., Peeters, M., Benedetti, F., Makris, L., et al. (2016) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 21
- Verified
Online psychological self-management intervention for testicular cancer survivors (e-TC 2.0): promising acceptability and preliminary efficacy, but limited feasibility
Smith, A. ‘., Rincones, O., Heiniger, L., Grimison, P., Tran, B., Stockler, M. R., Toner, G., Cohen, B., Olver, I., Klein, B., et al. (2020) · Journal of Psychosocial Oncology Research & Practice
Cancer survivorship and careDigital Mental Health Interventions
Cited by 8
- Verified
Malignancy, masculinities, and psychological distress: Comparisons made between men with testicular cancer and healthy controls
Dax, V., Ftanou, M., Tran, B., Lewin, J., & Wiley, J. F. (2024) · Psycho-Oncology
Gender Roles and Identity StudiesCancer survivorship and care
Cited by 3
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free